ArticleVaccine2016
Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV.
Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Oral immunization with filovirus-like particles partially protects IFNARScientific reports · 2026Article
- Revolutionizing vaccination: the marvel of nanovaccination technology.Molecular biology reports · 2025Review
- Article
- DC-targeting lentivectors for cancer immunotherapy.Immunotherapy advances · 2023Review
- Enhanced T-Cell Priming and Improved Anti-Tumor Immunity through Lymphatic Delivery of Checkpoint Blockade Immunotherapy.Cancers · 2022Article
- Orthogonal modular biosynthesis of nanoscale conjugate vaccines for vaccination against infection.Nano research · 2022Article
- Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic.International journal of pharmaceutics · 2021Review
- CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses.Vaccines · 2020Article
- Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials.Pharmaceutics · 2019Review
- Article
- The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector.BMC immunology · 2018Article
- Noninvasive vaccination against infectious diseases.Human vaccines & immunotherapeutics · 2018Review
- Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality.Molecular pharmaceutics · 2018Article
- Viruses Seen by Our Cells: The Role of Viral RNA Sensors.Journal of immunology research · 2018Review
- Retrovirus-Based Virus-Like Particle Immunogenicity and Its Modulation by Toll-Like Receptor Activation.Journal of virology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Human Immunodeficiency Virus (HIV) Virus-Like Particles (VLPs) composed of HIV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.